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A B S T R A C T
The pathogenesis of renal hypertension has not yet been fully clarified. As the potential role of endothelin-1 (ET-1) and
nitric oxide (NO) has been postulated, their concentrations were determined in plasma and urine of diabetic patients.
The study included 30 diabetic patients (both IDDM and NIDDM) with initial or advanced diabetic nephropathy (de-
creased endogenous creatinine clearance, proteinuria) and 20 healthy control subjects. The correlation with blood pres-
sure and other renal function parameters was monitored and compared with the control group. Also, the effect of ACE in-
hibitors (ACEI) on ET-1 and NO patterns was monitored in correlation with arterial hypertension. In diabetic patients
that did not receive ACEI therapy, the increase in plasma ET-1 was associated with both systolic and diastolic blood pres-
sure elevation, whereas in those administered ACEI the increase in plasma ET-1 was associated with a systolic blood
pressure decline. In addition, the increase in plasma NO was accompanied by a statistically significant decline of both
systolic and diastolic blood pressure in diabetic patients receiving ACEI.
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Introduction
The pathogenesis of hypertension in diabetes mellitus
has not yet been completely elucidated, however, it has
been definitely found to be at least in part due to the in-
crease in the intravascular volume of extracellular fluid.
Two stages have been identified in the development of di-
abetic nephropathy, characterized by completely differ-
ent defects of renal function: hyperfiltration as the main
early functional impairment, and progressive reduction
of glomerular filtration with the development of chronic
renal insufficiency characteristic of the late stage of dia-
betic nephropathy1,2. The major clinical feature of dia-
betic nephropathy is proteinuria1–3. Arterial hyperten-
sion develops with the progression of proteinuria and
reduction of glomerular filtration. The role of endo-
thelin-1 (ET-1) and nitric oxide (NO) in the pathogenesis
of hypertension in diabetes has recently been increas-
ingly investigated. Vascular endothelium plays a crucial
role in the vascular tone regulation through the produc-
tion of vasoactive substances. Vasoactive substances in-
clude ET-1 as a vasoconstrictor and NO as a vasodilator.
ET-1 as the most potent vasoconstrictor identified to
date enhances sympathetic activity3–9, increases arterial
blood pressure, and decreases plasma flow and glomeru-
lar filtration, thus reducing natriuresis and diuresis10–13.
ET-1 synthesis is stimulated by ischemia, stress, nephro-
toxic drugs as well as by various humoral factors such as
glucose and insulin. It has been postulated that endothe-
lial activation in diabetes may enhance vascular produc-
tion of ET-1, which leads to glomerular lesion by increas-
ing vasoconstriction, mesangial cell proliferation and
glomerular permeability, and to the development of arte-
rial hypertension13,14.
NO is a free gaseous radical that is involved in a vari-
ety of physiological processes. NO leads to vasodilation,
and inhibits vascular smooth muscle proliferation as well
as platelet adhesion and aggregation. NO is formed from
L-arginine by the action of NO-synthetase in vascular
endothelium. It is a potent vasodilator involved in vascu-
lar tone regulation15–17. In diabetic patients, vascular en-
dothelial dysfunction results in a reduced production or
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release of NO15. Impaired metabolic control and elevated
blood glucose concentrations lead to endothelial dysfunc-
tion, which in turn entails a decreased NO production,
increased vasoconstriction, and potential development of
arterial hypertension in diabetics16.
The aim of the present study was to determine the
concentrations of ET-1 and NO in plasma and urine of di-
abetic patients with initial or advanced diabetic nephro-
pathy, and to compare them with those in a control group
of healthy subjects. The study also addressed the associa-
tion of ET-1 and NO with arterial hypertension accord-
ing to the presence or absence of ACE inhibitors (ACEI)
in patient therapy.
Patients and Methods
The study included 30 diabetic patients (15 male and
15 female), mean age 65 years, with initial or advanced
diabetic nephropathy (decreased endogenous creatinine
clearance and proteinuria). The patients were divided
into two groups according to type of diabetes mellitus
into insulin dependent (IDDM) and non-insulin depend-
ent (NIDDM) diabetes mellitus. All study patients un-
derwent clinical examination, renal ultrasonography
(kidney size), and determination of serum hemoglobin,
serum creatinine concentrations, creatinine clearance
and body mass index (BMI).
ET-1 and NO were determined in serum and morning
urine sample. ET-1 was determined by ELISA using an
ET test kit with enzyme immunologic analysis designed
for direct determination of ET in biological fluids5.
Determination of NO includes measurement of its
stable product (NO2) based on Griess reaction and colori-
metric determination of stained product concentration.
Urine nitrites were also determined by use of Griess re-
agent. Nitrite concentration was assessed by reading the
reaction solution absorption at 540 nm18. Protein was
quantitatively determined in 24-h urine.
Based on funduscopy findings, used to assess the
presence of microangiopathic lesions, patients were divi-
ded into two groups with proliferative and nonprolife-
rative diabetic retinopathy. Glycated hemoglobin (HbA1c)
was used for diabetic control assessment. Blood pressure
was monitored throughout the study period. Elevated
blood pressure was recorded in 16 and normal blood
pressure in 14 patients. Data on the duration of diabetes
mellitus, patient habits (cigarette smoking) and ACEI
therapy were obtained from patient histories. Control
group included 20 healthy subjects (5 male and 15 fe-
male), mean age 63 years. Body mass index in this group
was between 25–30 (mean 27).
Statistical analysis was performed by use of Kolmogo-
rov-Smirnov goodness of fit test, to determine whether
the distribution of values of a particular variable differed
significantly from the normal gaussian distribution. On
determination of significance of interval variable differ-
ences, Mann-Whitney nonparametric test was used for
differences between two independent groups, and Wilco-
xon nonparametric test for differences between depend-
ent samples.
Results
A higher plasma concentration of ET-1 was measured
in diabetic patients as compared with control subjects
(10.63 pg/mL vs. 8.10 pg/mL); however, the difference did
not reach statistical significance (p=0.23). Urine concen-
tration of ET-1 was also higher in diabetic patients than
in control subjects (12.05 pg/mL vs. 9.66 pg/mL); this dif-
ference was not statistically significant either. Plasma
concentration of NO was statistically significantly higher
in diabetics than in healthy control subjects (7.49 mmol/L
vs. 5.88 mmol/L; p=0.0001). Urine concentration of NO
was 13.61 mmol/L in diabetic patients and 11.02 mmol/L
in control subjects; the difference was not statistically
significant (p=0.312). The main clinical laboratory pa-
rameters of diabetic patients and control subjects are
shown in Tables 1 and 2, respectively.
There was no statistically significant difference in
plasma and urine concentrations of ET-1 and NO be-
tween IDDM and NIDDM patients. These two groups
showed no statistically significant differences in the level
of blood pressure, diabetes duration, proteinuria and
HbA1C. These variables yielded no statistically significant
differences between the subgroups of diabetic patients with
proliferative and nonproliferative retinopathy.
In the group of diabetic patients there were 87% of
nonsmokers and 13% of cigarette smokers. Kidney size
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TABLE 1
CLINICAL LABORATORY FINDINGS IN DIABETIC PATIENTS
Plasma
endothelin
(pg/mL)
Plasma NO
(mmol/L)
Urine
endothelin
(pg/L)
Urine NO
(mmol/L)
Age (yrs)
Kidney size
(mm)
Creatinine
(mmol/L)
Creatinine
Clearance
(mmol/L)
N 30 30 30 30 30 30 30 30
Arithmetic mean 10.6367 7.4950 12.0583 13.6190 64.33 107.1667 190.80 29.5
Range 30.19 4.17 20.50 61.44 36 63 550 80
Minimum 3.91 5.48 4.33 5.36 45 85.00 50 8
Maximum 34.1 9.65 24.83 66.80 81 148.00 600 90
N – number of diabetic patients, NO – nitric oxide
determined by echosonography was 107.16 mm in the di-
abetic group and 105.70 mm in the control group, the dif-
ference being not statistically significant (p=0.856). Serum
Hb concentration was statistically significantly lower in
diabetics than in control subjects (118.10 g/L vs. 133.65
g/L; p=0.002), whereas serum creatinine concentration
statistically significantly higher in the former (190.88
mmol/L vs. 88.25 mmol/L; p=0.004). Creatinine clearance
in diabetic patients was 29,5 mmol/. In the control group
the creatinine clearance was 106 mmol/, which was statis-
tically significant difference (p=0.004). (Table 1).
There is no statistically sisgnificant difference in body
mass index between diabetic patients (BMI=27) and
healthy control (25). The mean blood pressure level was
160/92 mm Hg in diabetics and 120/80 mm Hg in control
subjects, yielding a statistically significant difference (p=
0.0001). There was a positive correlation between diabe-
tes mellitus and both systolic (rs 0.369; p=0.0001) and
diastolic (rs 0.269; p=0.001) blood pressure (Table 3).
Sixteen (53.3%) diabetics received ACEI therapy, whe-
reas 14 (46.7%) did not receive this medication. An in-
crease in systolic blood pressure with the rise in plasma
ET-1 was observed in the latter, as indicated by the high
value of the regression coefficient square for square re-
gression R2=0.4239, yielding a curve that followed the
value distribution of the study variables (Figure 1). The
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TABLE 3
CLINICAL LABORATORY FINDINGS IN DIABETIC PATIENTS
Systolic blood
pressure (mm Hg)
Diastolic blood
pressure (mm Hg)
Diabetes
duration (yrs)
Proteinuria
(g/24 h)
HbA1c (%)
N 30 30 30 30 30
Arithmetic mean 160.17 92.00 10.17 2.3263 7.60
Range 90 60 22 8.15 10.4
Minimum 130 60 2 0.25 3.4
Maximum 220 120 24 8.40 13.8
N – number of diabetic patients, HbA1c – glycated hemoglobin
TABLE 2
DESCRIPTIVE STATISTICS DATA IN CONTROL GROUP
Group
Plasma
endothelin
(pg/mg)
Plasma NO
(mmol/L)
Kidney size
(mm)
Creatinine
(mmol/L)
Creatinine
Clearance
(mmol/L)
Systolic blood
pressure
(mm Hg)
Diastolic blood
pressure
(mm Hg)
Control N 20 20 20 20 20 20 20
Arithmetic mean 8.103 5.8875 105.70 88.25 106 122.25 81.25
Median 7.180 5.6800 105.00 85.50 103 120.00 80.00
N – number of control subjects, NO – nitric oxide
Fig. 1. Systolic blood pressure levels according to plasma endo-
thelin-1 (ET-1) in diabetic patients not receiving ACEI.
Fig. 2. Diastolic blood pressure levels according to plasma endo-
thelin-1 (ET-1) in diabetic patients not receiving ACEI.
subgroup of diabetic patients not receiving ACEI showed
a rise in diastolic pressure with ET-1 increase (Figure 2);
regression coefficient for square model R2=0.1560. The
subgroup of diabetic patients treated with ACEI showed
a marked systolic pressure decline with the rise in plas-
ma ET-1 (Figure 3), as indicated by the regression coeffi-
cient square for square regression R2=0.1474, and a
nonsignificant decline of diastolic blood pressure (R2=
0.0725).
The group of diabetic patients as a whole, irrespective
of ACEI therapy, showed a mild decrease of systolic blood
pressure with the increase in plasma NO, however, with-
out statistical significance (R2=0.0096) (Figure 4). In the
subgroup of diabetics receiving ACEI, there was a statis-
tically significant decrease in systolic blood pressure with
the increase in plasma NO; square of regression coeffi-
cient for linear model R2=0.1402 (Figure 5). This sub-
group showed an obvious tendency of diastolic blood
pressure decline with the increase in plasma NO; model
R2=0.1065 (Figure 6). The subgroup of diabetic patients
not receiving ACEI showed a mild increase in systolic
blood pressure and an increase in diastolic blood pres-
sure with the rise in plasma NO, yet without statistical
significance (R2=0.1115 and R2=0.2806, respectively)
(Figures 7 and 8).
Discussion
Diabetic nephropathy is the most common cause of
chronic renal insufficiency. Initially it manifests with
microalbuminuria. The mechanisms involved in the oc-
currence of microalbuminuria should be properly under-
stood to be able to prevent renal complications in dia-
betic patients (14). Vascular endothelium plays a crucial
role in the regulation of vascular tone by producing
vasoactive substances, i.e. vasodilators such as NO and
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Fig. 3. Systolic blood pressure levels according to plasma endo-
thelin-1 (ET-1) in diabetic patients receiving ACEI.
Fig. 4. Systolic blood pressure levels according to plasma nitric
oxide (NO) in diabetic patients not receiving ACEI.
Fig. 5. Systolic blood pressure levels according to plasma nitric
oxide (NO) in diabetic patients receiving ACEI.
Fig. 6. Diastolic blood pressure levels according to plasma nitric
oxide (NO) in diabetic patients receiving ACEI.
prostacycline, and vasoconstrictors such as thromboxane
A2 and ET-1. The synthesis of ET-1 is stimulated by
ischemia, stress, nephrotoxic drugs as well as by a vari-
ety of humoral substances such as glucose and insulin. It
has been postulated that endothelium activation in dia-
betes can increase the vascular production of ET-1,
which then leads to glomerular lesion by increasing the
vasoconstriction, mesangial cell proliferation and glo-
merular permeability1,13,14. Both in vivo and in vitro
studies suggest that NO-mediated vasodilation can be re-
duced in diabetes mellitus. NO is a potent vasodilator
that is involved in the regulation of vascular tone in hu-
mans. Normal vascular endothelium prevents develop-
ment of atherosclerosis by the formation and release of
NO. Besides its vasodilating action, NO inhibits prolifer-
ation of smooth muscle vasculature as well as platelet ad-
hesion and aggregation15.
Hyperglycemia leads to dysfunction of the vascular
adrenergic system, impairment of NO synthesis, and im-
paired response of NO system cells through a reversible
mechanism that includes superoxide anions. In uncon-
trolled diabetes mellitus, endothelial dysfunction results
in a reduced NO production and potential development
of hypertension16. In our study, the group of diabetic pa-
tients had higher plasma and urine concentration of
ET-1 as compared with control subjects, although the dif-
ference was not statistically significant. The study in-
cluded patients with hypertension, uncontrolled diabetes
mellitus, obesity, and variable serum creatinine levels.
Hypertension, poor metabolic control, obesity and de-
creased glomerular filtration are known to influence the
activity of ET-114.
Vermes et al. found an increased plasma ET-1 in
NIDDM patients with proteinuria and normal plasma
ET-1 in NIDDM patients with microalbuminuria19. Re-
cent studies have been focused on the role of circulating
ET-1 in early diabetic nephropathy. Elevated plasma con-
centrations of ET-1 have been reported in NIDDM pa-
tients with or without microalbuminuria20, suggesting
that the vascular production of ET-1 might be enhanced
by endothelial activation in diabetes mellitus, thus in-
creasing the vasoconstriction, mesangial cell prolifera-
tion and glomerular permeability, which ultimately lead
to glomerular lesion19,20. In experiments on rats with im-
paired renal function, plasma ET-1 concentration was
normal, whereas urinary excretion of ET-1 was increa-
sed20. De Mattia et al. measured circulating and urine
ET-1 concentrations in NIDDM patients with or without
microalbuminuria, and compared ET-1 concentration be-
tween hypertensive and normotensive patients. They
found higher levels of circulating ET-1 in NIDDM pa-
tients irrespective of the presence or absence of micro- al-
buminuria14. These data support the hypothesis accord-
ing to which NIDDM influences vascular production of
ET-1 via early endothelial activation and before the oc-
currence of microalbuminuria. The 24-h urinary excre-
tion of ET-1 was considerably reduced in NIDDM pa-
tients with or without microalbuminuria. Urine con-
centration of ET-1 showed no correlation with plasma
ET-1, urinary albumin excretion, or creatinine clearance.
In this study, the values of creatinine and blood glucose
were normal, in contrast to our study, where elevated lev-
els of creatinine, blood glucose and HbA1c were recorded.
In the present study, we found a positive correlation
between plasma ET-1 and blood pressure in the group of
diabetic patients. Diabetic patients were divided into
subgroups according to the presence or absence of ACEI
therapy. The subgroup of diabetic patients not receiving
ACEI showed a positive correlation between plasma
ET-1, and both systolic and diastolic blood pressure. In
the subgroup of diabetic patients receiving ACEI, how-
ever, the correlation between plasma ET-1 and systolic
blood pressure was negative.
In our study, diabetic patients showed higher plasma
NO concentration than control subjects. Rodrigez-Manas
et al. assessed the impact of glycemic control on the NO
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Fig. 7. Systolic blood pressure levels according to plasma nitric
oxide (NO) in diabetic patients not receiving ACEI.
Fig. 8. Diastolic blood pressure levels according to plasma nitric
oxide (NO) in diabetic patients not receiving ACEI.
system function in type 1 diabetes mellitus and found
NO response dysfunction to be only present in the early
stage of the disease (duration of less than 3 years), in pa-
tients without clinical evidence for vascular disease16. In
diabetics, intensive oxidative stress was observed in the
very early stage of the disease, including children and ad-
olescents. Oxidative stress is associated with the meta-
bolic state in diabetes21. Oxidative stress and NO inacti-
vation by the vascular superoxide anion O2 play the key
role in the pathogenesis of vascular diseases, including
hypertension, atherosclerosis, hypercholesterolemia, di-
abetes mellitus, cardiac insufficiency, etc. In most cases,
a rise in O2 decreases endothelial vascular relaxation me-
diated by NO, thus inactivating endogenous NO21.
In the present study, a mild yet statistically nonsigni-
ficant decrease in systolic blood pressure with the incre-
ase in plasma NO was observed in the group of diabetic
patients as a whole. However, a statistically significant
decrease of both systolic and diastolic blood pressure
with the increase in plasma NO was recorded in the sub-
group of diabetic patients receiving ACEI.
In conclusion, the present study demonstrated the
correlation of plasma ET-1 and NO concentrations with
systolic and diastolic blood pressure to depend on the
presence or absence of ACEI therapy. Plasma ET-1 and
NO were determined during the treatment with anti-
hypertensive agents (mostly patients with severe and un-
controlled hypertension). Study results suggested the re-
lationship of blood pressure with ET-1 and NO to be
modified by ACEI therapy. Additional studies are needed
with ET-1 and NO determined before the introduction of
ACEI treatment, in order to more precisely identify the
correlation of these parameters with blood pressure.
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ULOGA ENDOTELINA-1 I NITRI^KOG OKSIDA U PATOGENEZI
HIPERTENIZIJE DIJABETI^ARA
S A @ E T A K
Patogeneza bubre`ne hipertenzije nije u potpunosti jasna, a odre|enu ulogu mogu imati endotelin-1 (ET-1) i nitri~ki
oksid (NO)(1). Zbog toga smo u ovom istra`ivanju odre|ivali koncentraciju ET-1 i NO u plazmi i u urinu u dijabeti~ara.
U istra`ivanje je uklju~eno 30 ispitanika sa {e}ernom bole{}u (IDDM i NIDDM) s po~etnom ili razvijenom dijabeti~kom
nefropatijom (smanjen klirens endogenog kreatinina, proteinurija) i 20 zdravih kontrolnih ispitanika. Pratila se pove-
zanost s krvnim tlakom i drugim parametrima bubre`ne funkcije te uspore|ivala s kontrolom. Tako|er, smo pratili
u~inak ACE – inhibitora (ACEI) na odnos ET-1 i NO u korelaciji s arterijskom hipertenzijom. U bolesnika sa {e}ernom
bole{}u koji nisu koristili ACEI u terapiji uo~en je porast plazmatske koncentracije ET-1 s porastom sistoli~kog i dija-
stoli~kog krvnog tlaka, dok u dijabeti~ara koji su lije~eni ACEI s porastom plazmatske koncentracije ET-1 postoji ten-
dencija pada sistoli~kog krvnog tlaka. U dijabeti~ara lije~enih ACEI, utvr|en je statisti~ki zna~ajan pad sistoli~kog i
dijastoli~kog krvnog tlaka s porastom plazmatske koncentracije NO.
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